Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/25/2025 | $20.00 | Neutral | Goldman |
| 7/30/2025 | $46.00 | Strong Buy | Raymond James |
| 6/30/2025 | $42.00 | Buy | H.C. Wainwright |
| 4/30/2025 | $41.00 | Buy | Guggenheim |
| 4/2/2025 | $14.00 | Sector Outperform → Sector Perform | Scotiabank |
| 3/7/2025 | $50.00 | Sector Outperform | Scotiabank |
| 1/22/2025 | $30.00 | Hold | Stifel |
| 11/22/2024 | $45.00 | Outperform | Evercore ISI |
8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
10-Q - Edgewise Therapeutics, Inc. (0001710072) (Filer)
8-K - Edgewise Therapeutics, Inc. (0001710072) (Filer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
BOULDER, Colo., Nov. 12, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc. ("Edgewise" or the "Company"), (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced that on November 10, 2025, Edgewise granted an inducement stock option to purchase a total of 262,500 shares of Edgewise's common stock and an award of inducement restricted stock units ("RSU award") covering a total of 43,750 shares of Edgewise's common stock to Michael Nofi, in connection with the commencement of his employment as Chief Financial Officer of the Company, effective today, pursuant to Edgewise's 2024 Induce
BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a
BOULDER, Colo., Nov. 7, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced that management will participate in the following investor conferences: Guggenheim 2nd Annual Healthcare Innovation ConferenceFireside chat: Tuesday, November 11, 2025 at 8:30 am ET Piper Sandler 37th Annual Healthcare ConferenceFireside chat: Tuesday, December 2, 2025 at 2 pm ET 8th Annual Evercore Healthcare ConferenceFireside chat: Wednesday, December 3, 2025 at 3:25 pm ET The webcasts can be found on the Edgewise Event
Goldman initiated coverage of Edgewise Therapeutics with a rating of Neutral and set a new price target of $20.00
Raymond James initiated coverage of Edgewise Therapeutics with a rating of Strong Buy and set a new price target of $46.00
H.C. Wainwright initiated coverage of Edgewise Therapeutics with a rating of Buy and set a new price target of $42.00
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
4 - Edgewise Therapeutics, Inc. (0001710072) (Issuer)
BOULDER, Colo., Nov. 10, 2025 /PRNewswire/ -- Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company developing novel therapeutics for muscular dystrophies and serious cardiac conditions, today announced the appointment of Michael Nofi, as Chief Financial Officer (CFO), effective November 10, 2025. Mr. Nofi joins Edgewise after serving as Chief Accounting Officer (CAO) at SpringWorks Therapeutics, Inc. Mr. Nofi will succeed Edgewise CFO, R. Michael Carruthers, who is retiring. "As we enter a pivotal stage in our Company's evolution, we a
Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a leading muscle disease biopharmaceutical company, today announced the appointment of biotechnology industry veteran Arlene Morris to its Board of Directors. Ms. Morris has extensive experience in the pharmaceutical and biotechnology industries serving in numerous executive management and board roles. "With over 30 years of exceptional leadership experience in the biotech industry, we are delighted to welcome Arlene to our Board," said Kevin Koch, Ph.D., President and Chief Executive Officer. "Arlene brings invaluable expertise in strategic development and operational excellence, and we are thankful to count her as a valued advisor as we contin
– President and Chief Medical Officer (CMO) of BridgeBio Pharma and Former CMO of MyoKardia brings strong cardiovascular expertise to Edgewise – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, targeted, small molecule therapies for individuals with devastating muscle disorders, announced today the appointment of Jonathan C. Fox, M.D., Ph.D., FACC, to its Board of Directors. Dr. Fox brings considerable expertise in clinical development and regulatory strategy to Edgewise, serving currently as President and CMO at BridgeBio Pharma, and previously as CMO at MyoKardia, where he was one of the inventors of Camzyos
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G/A - Edgewise Therapeutics, Inc. (0001710072) (Subject)
SC 13G - Edgewise Therapeutics, Inc. (0001710072) (Subject)
– Remarkable North Star Ambulatory Assessment scale (NSAA) improvements relative to BMD natural history trajectories – – Significant decrease in levels of serum creatine kinase (CK) and fast skeletal muscle troponin I (TNNI2), enzyme biomarkers strongly associated with muscle damage caused by BMD – – EDG-5506 continues to be well-tolerated with no serious adverse events observed – – Management hosting webcast to discuss findings on September 12 at 8:30 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today pos
– EDG-5506 treatment significantly lowered muscle damage biomarkers in adults with BMD – – BMD patients were more active during 2 months of dosing with EDG-5506 relative to activity measured in BMD patients in the Phase 1 study – – EDG-5506 was well tolerated with no serious adverse events observed; safety profile supported dose escalation to 15 mg daily for all patients – – Management hosting webcast to discuss findings on June 21 at 9:00 a.m. Eastern Time – Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for the treatment of rare muscle disorders, announced today positive 2-month
- Edgewise management to host webcast conference call on Tuesday, June 21, 2022 at 9 a.m. Eastern Time - - Additional presentations and posters featuring EDG-5506 to be featured at the New Directions Conference and the upcoming PPMD Annual Conference - Edgewise Therapeutics, Inc., (NASDAQ:EWTX), a clinical-stage biopharmaceutical company focused on developing orally bioavailable, small molecule therapies for rare muscle disorders, today announced that new 2-month interim data from the ARCH open label study of EDG-5506 in individuals with BMD will be presented at the 2022 New Directions in Biology and Disease of Skeletal Muscle Conference, being held June 20-23, 2022. Edgewise ARCH Interi